Compare EMBC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBC | KURA |
|---|---|---|
| Founded | 1924 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.1M | 1.1B |
| IPO Year | 2021 | 2015 |
| Metric | EMBC | KURA |
|---|---|---|
| Price | $5.72 | $10.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $4.00 | ★ $32.00 |
| AVG Volume (30 Days) | 915.5K | ★ 1.7M |
| Earning Date | 11-24-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 20.90 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $42.46 |
| Revenue Next Year | $5.59 | $116.75 |
| P/E Ratio | $5.62 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $2.77 | $7.36 |
| 52 Week High | $14.91 | $13.90 |
| Indicator | EMBC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 37.93 |
| Support Level | $4.84 | $8.45 |
| Resistance Level | $5.91 | $12.21 |
| Average True Range (ATR) | 0.23 | 0.48 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 73.02 | 13.35 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.